Clinical Trial

Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND007 Cell Therapy

Name: Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND007 Cell Therapy — clinical trial record (NCT07359963)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

This study is a prospective, single-arm, dose-escalation exploratory clinical trial to investigate the safety, tolerability and preliminary efficacy of REGEND007 stem cell preparation administered by intravenous infusion in the treatment of idiopathic pulmonary fibrosis (IPF), with a follow-up period of 12 weeks.

Trial Details

NCT Number	NCT07359963
Lead Sponsor	Regend Therapeutics
Conditions	Idiopathic Pulmonary Fibrosis (IPF)
Enrollment	12 participants
Start Date	2026-02-15
Primary Completion	2027-02-15 (estimated)
Study Completion	2027-06-15 (estimated)
Updated on ClinicalTrials.gov	2026-01-22